Clinical Pharmacology of a New Ureidopenicillin: Bay K 4999
作者:
H. Lode,
W. Tomas,
P. Koeppe,
J. Wagner,
期刊:
Chemotherapy
(Karger Available online 1980)
卷期:
Volume 26,
issue 2
页码: 81-90
ISSN:0009-3157
年代: 1980
DOI:10.1159/000237887
出版商: S. Karger AG
关键词: New ureidopenicillin;Pharmacokinetics;Comparison with mezlocillin;Clinical and bacteriological results;Side effects
数据来源: Karger
摘要:
A new semisynthetic ureidopenicillin (Bay K 4999) demonstrates favorably in vitro antibacterial efficacy against human-pathogenic gram-negative rods in comparison to mezlocillin and azlocillin. A comparative pharmacokinetic study was done with 10 test subjects after 30 min intravenous infusion of 4.0 g of Bay K and mezlocillin, respectively. The serum concentration course during a period of 10 h showed an open three-compartment model for both antibiotics. The urine recovery of Bay K 4999 during 24 h was only 32.6 ± 4.3% of the applied dose. In three test subjects with normal renal function, the average renal clearance of Bay K was 61.0, the total serum clearance was 409.2 ml/min/1.73 m2. 31 patients were treated with a daily dose of 3 × 1.0–2.0 g Bay K for severe bronchopulmonary, UTI and cholangiogenic infections. The therapeutic results were good; the relatively high number of side effects should be further investigated in animal studies and require more clinical experie
点击下载:
PDF
(2782KB)
返 回